The present invention provides treatment regimens for treating diseased
prostate tissue, including the steps of chemically ablating
prostate tissue and coadministering an
antiandrogen. In some embodiments,
prostate tissue is chemically ablated by injection of
ethanol, or an injectable gel comprising
ethanol, into prostate tissue. Steroidal and non-steroidal antiandrogens are suitable antiandrogens. One suitable non-steroidal
antiandrogen is
bicalutamide. The
treatment regimen is suitable for treatment of prostate tissue diseases including benign prostatic
hyperplasia and prostatic
carcinoma. The invention further provides a
treatment regimen for treating benign prostatic
hyperplasia, including the steps of damaging prostate tissue and coadministering an
antiandrogen. Also provided by the present invention is a kit for treating a human male, including a means for necrosing prostate tissue, an antiandrogen
drug, and a means for administering the antiandrogen
drug. A kit including a first
surgical device for delivering a chemoablation fluid to prostate tissue transurethrally, an antiandrogen
drug such as
bicalutamide, and a second
surgical device for administering the antiandrogen drug, is further provided.